chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy, Vaccination site lymphadenopathy
Clinical narrative: Swollen node at the injection site; Glands under the arm has swollen; This is a spontaneous report from a contactable consumer. A 24-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration in the left arm on 29Jun2021 at 18:30 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration in the left arm on 08Jun2021 at 17:30 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. On 30Jun2021, the patient had a larger swollen node at the injection site and glands under the arm had swollen as well. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events larger swollen node at the injection site and glands under the arm had swollen were not resolved at the time of this report.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Arm pain; This is a spontaneous report from a non-contactable physician, the patient. A 72-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on 01Jul2021 at 14:00 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Jul2021 at 16:00 the patient experienced arm pain. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event arm pain was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: tingling and numbness in arm and hand; tingling and numbness in arm and hand; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 01Jul2021 at 10:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Jul2021 at 07:00, the patient experienced tingling and numbness in arm and hand where she had received the shot. The event did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event tingling and numbness in arm and hand was not resolved at the time of this report.  No follow-up attempts are possible; information about lot number cannot be obtained. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in ears; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0171) via an unspecified route of administration in the left arm on 17May2021 at 17:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Patient did not receive any other medication within two weeks of vaccination. The patient had no known allergies to food, medication or other products. On 02Jun2021, about two weeks after vaccination, the patient experienced ringing in ears. The patient did not receive any treatment for the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event ringing in ears was not recovered at the time of this report.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Somnolence
Clinical narrative: Taday 7.3.21 I felt numbness my left hand. More below joint. Previous night was slipness.; Taday 7.3.21 I felt numbness my left hand. More below joint. Previous night was slipness.; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0181) via an unspecified route of administration in the left arm on 30Jun2021 at 19:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination were not reported. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0181) via an unspecified route of administration in the left arm on 09Jun2021 at 19:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Jul2021, previous night, the patient experienced slipness. On 03Jul2021, the day of report, the patient felt numbness in his left hand. More below joint. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events previous night, the patient experienced slipness, on the day of report, the patient felt numbness in his left hand; more below joint was not resolved at the time of this report.
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Pain, Pyrexia
Clinical narrative: had high fever of 103; headaches; body aches; fatigue; This is a spontaneous report from a contactable physician (Pfizer colleague). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number and expiration date were not reported), dose 2 via an unspecified route of administration on 07Jun2021 as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Patient historically took bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number and expiration date were not reported), dose 1 via an unspecified route of administration on as dose 1, single for covid-19 immunisation. On an unspecified date in Jun2021, the patient experienced had high fever of 103, headaches, body aches, fatigue. Reportedly, after 2nd dose of COVID vaccine on 07Jun (24 days ago) patient had high fever of 103, headaches, body aches, and fatigue. As of today, 24 days later, patient still has a high fever of 101 and headaches, body aches, and fatigue. The patient underwent lab tests and procedures which included high fever: 103 on Jun2021 (24 days ago, had high fever of 103) and high fever: 101 on 01Jul2021 (As of today, 24 days later, still has a high fever of 101). The outcome of the events was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Oligomenorrhoea
Clinical narrative: Menstrual Cycle extended.; Inappropriate schedule of vaccine administered; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date in Jun2021 at 17:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included pernicious anemia, bi-lateral carpal tunnel, costochondritis and degenerative disc disease. The patient had known allergy to penicillin. The patient previously received ibuprofen (MOTRIN) and amoxicillin (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Concomitant medications included cyanocobalamin injections (B-12) for unknown indication and allergy medicine unspecified (MANUFACTURER UNKNOWN) both from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Apr2021 at 08:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. On an unknown date in Jun2021 the patient's menstrual cycle extended. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19.The clinical outcome of the event menstrual cycle extended was unknown at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Contusion, Discomfort, Magnetic resonance imaging, Mobility decreased, Pain
Clinical narrative: my spine was sore to the touch like a bruise or something; my spine was sore to the touch like a bruise or something; pain; can't bend down to tie my shoes or put on pants; constant pressure and pulling sensation on my spine; constant pressure and pulling sensation on my spine; This is a spontaneous report from a contactable consumer. A 56-year-old female patient received dose 1 of BNT162B2 (Pfizer-BIONTECH COVID-19 Vaccine), via an unspecified route of administration, administered in the left arm on 29Mar2021 at 12:00 (at the age of 56-years-old) (Batch/Lot Number: ER8733) single, for COVID-19 immunization. The patient's medical history was not reported. The patient had no other vaccines in four weeks, did not have COVID prior to vaccination, and was not pregnant. Concomitant medication included levothyroxine sodium (SYNTHROID) taken for an unspecified indication, start and stop date were not reported. The patient previously took Levaquin and experienced drug allergy. The day after the patient's first COVID vaccine, on 30Mar2021 at 08:00 AM, it was reported that her spine was sore to the touch like a bruise or something. The pain had continued to get worse now for the past three months. She can't bend down to tie her shoes or put on pants. She had to sit on her bed to get dressed. She was a healthy active person before the vaccine and she had never had a problem with her back in the past. She had a constant pressure and pulling sensation on her spine. The patient had X-rays and MRI (results unspecified) on an unspecified date and was looking at some type of therapy now since the other tests didn't show what was causing the pain. She was not COVID tested post vaccination. The patient received treatment for the events (unspecified; also reported as lumbar X-rays and MRI). Outcome of the events was not recovered.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Sensory disturbance, Spinal X-ray, Spinal pain, X-ray
Clinical narrative: my spine was sore to the touch like a bruise or something; my spine was sore to the touch like a bruise or something; pain; can't bend down to tie my shoes or put on pants; constant pressure and pulling sensation on my spine; constant pressure and pulling sensation on my spine; This is a spontaneous report from a contactable consumer. A 56-year-old female patient received dose 1 of BNT162B2 (Pfizer-BIONTECH COVID-19 Vaccine), via an unspecified route of administration, administered in the left arm on 29Mar2021 at 12:00 (at the age of 56-years-old) (Batch/Lot Number: ER8733) single, for COVID-19 immunization. The patient's medical history was not reported. The patient had no other vaccines in four weeks, did not have COVID prior to vaccination, and was not pregnant. Concomitant medication included levothyroxine sodium (SYNTHROID) taken for an unspecified indication, start and stop date were not reported. The patient previously took Levaquin and experienced drug allergy. The day after the patient's first COVID vaccine, on 30Mar2021 at 08:00 AM, it was reported that her spine was sore to the touch like a bruise or something. The pain had continued to get worse now for the past three months. She can't bend down to tie her shoes or put on pants. She had to sit on her bed to get dressed. She was a healthy active person before the vaccine and she had never had a problem with her back in the past. She had a constant pressure and pulling sensation on her spine. The patient had X-rays and MRI (results unspecified) on an unspecified date and was looking at some type of therapy now since the other tests didn't show what was causing the pain. She was not COVID tested post vaccination. The patient received treatment for the events (unspecified; also reported as lumbar X-rays and MRI). Outcome of the events was not recovered.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Urinary incontinence
Clinical narrative: Bladder leakage during the night time; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN8732) via an unspecified route of administration in the left arm on an unknown date in 2021 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history.  Concomitant medications included simvastatin (MANUFACTURER UNKNOWN); taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 27Mar2021 at 14:30 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. The patient previously took ampicillin and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Jun2021 at 23:00, about a month after the second shot, the patient started having bladder leakage during the night time. The patient had never had this happened and did not know if it was a side effect. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination the patient had not been tested for COVID-19. The clinical outcome of the event bladder leakage during the night time was not recovered at the time of this report.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Period started one week after and lasted 32 days; This is a spontaneous report from a contactable consumer(patient). A 49-year-old non-pregnant female patient received bnt162b2 (COMIRNATY, Solution for injection, Lot Number was not reported), via an unspecified route of administration on 23MAR2021,12:00 PM (at the age of 49-years-old) as DOSE 2, SINGLE into left arm for COVID-19 immunization. The patient took vaccine at hospital. The patient medical history was known allergies to penicillin and other concomitant medications were not reported. The patient took Historical Vaccine BNT162B2 (COMIRNATY, Solution for injection, Lot Number unknown), via an unspecified route of administration as DOSE 1, SINGLE for COVID-19 immunization. The patient did not received any other vaccine in four weeks but took other medication in 2 weeks. The patient was not pregnant at time of vaccination. It was reported no covid prior vaccination and Covid tested post vaccination. On 31Mar2021 the patient experienced period and lasted 32 days which resulted in doctor or other healthcare professional office/clinic visit. The patient did not received any treatment for the event. The outcome of the events was recovered with Sequel.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up. Information about lot/ batch number has been requested.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Pain in extremity, Restlessness
Clinical narrative: Pain in the upper left thigh; Weird restless sensation; Tiredness; Had the sensation that the neck could not support the head. As if head was about to fall off the neck. No pain, just the weird sensation.; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 08:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol, high triglycerides, high testosterone, high insulin (not diabetic) and overweight; all from unknown date. The patient had no known allergies reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 22Apr2021, a couple of weeks after vaccination, the patient had tiredness and sensation that her neck could not support her head. The patient felt as if her head was about to fall off her neck. The patient had no pain and just had a weird sensation, which lasted about 2 weeks. On an unknown date in May2021, the patient had pain in her upper left thigh after four weeks or so. The pain ranged from her outer kneed up to mid buttocks and it lasted about 1 week. The pain and weird restless sensation would come and go throughout the day. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness and sensation that her neck could not support her head, as if her head was about to fall off her neck and pain in her upper left thigh were resolved on an unknown date in May2021. The clinical outcome of the event weird restless sensation was not resolved, at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: I have been nauseous; This is a spontaneous report from a contactable nurse, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0181) via an unspecified route of administration in the left arm on 21Jun2021 at 14:45 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included trochanteric bursitis, osteoarthritis in knees and lower back, intractable migraines and allergy to crab apples. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included trazodone (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and unknown if ongoing. The patient previously received meloxicam (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 22Jun2021, starting the day after the first dose, the patient had been nauseous for two weeks as of the present day. The patient had spoken to her doctor and have no other symptoms than that. The event resulted in doctor or other healthcare professional office/clinic visit. The patient reported that the doctor prescribed Zofran but she could not take it. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event nauseous was not recovered at the time of this report.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Depression, Fatigue, Musculoskeletal stiffness, Pain in extremity
Clinical narrative: Sore wrists and forearms.; Sore wrists and forearms.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Jun2021 at 15:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included vitamin d deficiency and depression. The patient had no known allergies to medications, food, or other products. Concomitant medications included bupropion hydrochloride 300 milligram daily (WELLBUTRIN) and escitalopram oxalate 20 milligram daily (LEXAPRO). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Jun2021, the patient experienced sore wrists and forearms. The patient also experienced tight and stiff shoulders and lower back, fatigue, restlessness, depression. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event sore wrists and forearms, tight and stiff shoulders and lower back, fatigue, restlessness, depression was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Restlessness
Clinical narrative: Sore wrists and forearms.; Sore wrists and forearms.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; Tight and stiff shoulders and lower back, fatigue, restlessness, depression.; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Jun2021 at 15:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included vitamin d deficiency and depression. The patient had no known allergies to medications, food, or other products. Concomitant medications included bupropion hydrochloride 300 milligram daily (WELLBUTRIN) and escitalopram oxalate 20 milligram daily (LEXAPRO). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Jun2021, the patient experienced sore wrists and forearms. The patient also experienced tight and stiff shoulders and lower back, fatigue, restlessness, depression. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event sore wrists and forearms, tight and stiff shoulders and lower back, fatigue, restlessness, depression was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: muscle ache on left side of body after receiving first dose of vaccine; Fever; This is a spontaneous report from a contactable consumer. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 02Jul2021 as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. It was unknown that the patient received any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication was not reported. On an unknown date in Jul2021, the patient experienced fever and muscle ache on left side of body after receiving first dose of vaccine. It was reported that the patient was feeling better after a night rest and drinking plenty of fluids. The patient did not receive any treatment for the events. The adverse events did not result in doctor or other healthcare professional office/clinic visit or emergency room/department or urgent care. The clinical outcome of the event muscle ache on left side of body after receiving first dose of vaccine and fever was recovered on an unknown date in Jul2021 at the time of this report.   information about lot/batch number has been requested.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headaches; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 09Apr2021 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included possible gastroesophageal reflux disease (GERD) from an unknown date. It was unknown whether the patient had any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. Since 16Jun2021, the patient was having headaches for about a month. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headaches was not recovered at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Rash
Clinical narrative: Have what looks like mosquito bites all over the body, but mainly on the left side where I got my vaccine; I'm miserable; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 20Jun2021, the patient reported that she had what looked like mosquito bites all over her body, but mainly on the left side where she got her vaccine. The patient felt miserable. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event had what looked like mosquito bites all over her body, but mainly on the left side where she got her vaccine and felt miserable was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Irritable bowel syndrome, Lactose intolerance, Lymph node pain, Lymphadenopathy
Clinical narrative: Pain and some swelling in lmpyhnodes; Pain and some swelling in lmpyhnodes; Also developed lactose intolerance or ibs after injections; Also developed lactose intolerance or ibs after injections; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in 30Mar2021 at 13:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included spironolactone (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown date taken within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021 the patient experienced continued pain and some swelling in lmpyhnodes even after four months later. The patient had also developed lactose intolerance or ibs after injections. The patient never had tummy issues with eating certain foods until the shot. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. O The clinical outcome of the events continued pain and some swelling in lmpyhnodes, and lactose intolerance or ibs were not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia
Clinical narrative: On--going fever 100.8F within 24 hours after injection; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the right arm on 02Jul2021 at 13:30 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Other Medical history and was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other medication within 2 weeks prior to the COVID-19 vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0196) via an unspecified route of administration in the left arm on 12Jun2021 at 11:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 03Jul2021, the patient underwent test for body temperature and the result was 100.8 degrees Fahrenheit. On 03Jul2021 at 04:00, the patient experienced on-going fever of 100.8 F (degrees Fahrenheit) within 24 hours after injection. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the event. The clinical outcome of the event on-going fever was not recovered at the time of this report.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blister, Lip swelling
Clinical narrative: Lips swelled up; Blisters; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 26Apr2021 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. Medical history included uveitis in left eye and penicillin allergy. Concomitant medications included prednisolone (MANUFACTURER UNKNOWN) eye drops and birth control (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021, the patient experienced lips swelled up and blisters. Treatment received for the events was steroid cream (unspecified drug) and antibacterial cream (unspecified drug). The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lips swelled up and blisters were not recovered at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the arm right on an unknown date in 2021 (at the age of 20-year-old) as a single dose for COVID-19 immunisation.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lip blister, Lip swelling
Clinical narrative: Lips swelled up; Blisters; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 26Apr2021 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. Medical history included uveitis in left eye and penicillin allergy. Concomitant medications included prednisolone (MANUFACTURER UNKNOWN) eye drops and birth control (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021, the patient experienced lips swelled up and blisters. Treatment received for the events was steroid cream (unspecified drug) and antibacterial cream (unspecified drug). The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lips swelled up and blisters were not recovered at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the arm right on an unknown date in 2021 (at the age of 20-year-old) as a single dose for COVID-19 immunisation.
Age: 19.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Dizziness, Nausea
Clinical narrative: Started feeling dizzy and nauseous on Monday 28Jun and has progressively gotten worse.; Started feeling dizzy; Nauseous; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration on 27Jun2021 (at the age of 19-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had no known drug allergies. The patient did not take any concomitant medication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration on 04Jun2021 (at the age of 19-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Jun2021, the patient started feeling dizzy and nauseous and had progressively gotten worse. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the dizzy, and nausea and included treatment with Zofran initially for nausea and started Valium. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events feeling dizzy and nauseous and had progressively gotten worse were unknown at the time of this report.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, SARS-CoV-2 test
Clinical narrative: I had headache.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 13Jun2021 at 15:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications taken within two weeks of vaccination were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Jun2021 at 09:00, the patient had headache. No therapeutic measures were taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 02Jul2021, the patient underwent COVID-19 test via nasal swab and the result was negative. The clinical outcome of the event had headache was resolved on an unknown date in 2021.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Parosmia, Taste disorder
Clinical narrative: Began experiencing strange taste; strange smells; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 02May2021 at 16:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included bupropion (MANUFACTURER UNKNOWN) and escitalopram oxalate (LEXAPRO) all from an unknown date for an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 11Apr2021 at 16:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 04May2021 at 08:00, the patient experienced strange smells and taste within 48 hours of vaccine. There was a persistent soapy/floral smell that she experienced each day and certain food items had the same soapy taste. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of events strange smells and taste within 48 hours of vaccine, persistent soapy/floral smell, certain food items had the same soapy taste was not recovered at the time of this report.
Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Paraesthesia, Spinal pain
Clinical narrative: Tingling sensation in spine; Spine and Muscle soreness around mid spine.; Spine and Muscle soreness around mid spine.; This is a spontaneous report from a contactable consumer, the patient. A patient of unknown gender and unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 19Apr2021, as a single dose for COVID-19 immunisation. Medical history included asthma and depression. The patient had known allergies to peanuts, fresh fish, some raw fruit and veggies except leafy greens and citrus. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included bupropion (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN) and pseudoephedrine hydrochloride, cetirizine hydrochloride (ZYRTEC-D); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021, the patient experienced tingling sensation in spine followed by spine and muscle soreness around mid spine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tingling sensation in spine followed by spine and muscle soreness around mid spine was not recovered at the time of this report.  The batch/lot numbers for, BNT162b2, were not provided and will be requested during follow up.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Migraine
Clinical narrative: migraine; Severe Headache for 4 days and continuing.; This is a spontaneous report from a contactable consumer (patient). A 30-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 2 via an unspecified route of administration, administered in arm left on 01Jul2021 at 10:30 (at the age of 30 years old) (Batch/Lot Number: EW0179) as a single dose for COVID-19 immunisation. Medical history included COVID-19 from 12Mar2021 to 22Mar2021, pineapple allergy from an unknown date and unknown if ongoing, and penicillin allergy from an unknown date and unknown if ongoing. Concomitant medications included levothyroxine, liothyronine (NP THYROID) taken for an unspecified indication, start and stop date were not reported; escitalopram (ESCITALOPRAM) taken for an unspecified indication, start and stop date were not reported; colecalciferol (VITAMIN D [COLECALCIFEROL]) taken for an unspecified indication, start and stop date were not reported; and ethinylestradiol, etonogestrel (NUVARING) taken for an unspecified indication, start and stop date were not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) on10Jun2021 at 12:15pm (at the age of 30 years old) (lot number: EW0169/ expiration date: not provided) as a single dose in the left arm for Covid-19 immunizzation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 02Jul2021 at 03:00, the patient experienced migraine (disability) which required a physician's office visit and severe headache for 4 days and continuing. Therapeutic measures were taken as a result of migraine included magnesium supplement. The patient did not receive treatment for the event headache. The outcome of the event migraine was recovered with sequel. The outcome of the event headache was not recovered.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Urticaria
Clinical narrative: Developed a full body rash with hives; Developed a full body rash with hives; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0198) via an unspecified route of administration in the right arm on 03Jul2021 at 15:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included depression. Concomitant medications included desvenlafaxine succinate monohydrate (PRISTIQ) and ethinylestradiol, ferrous fumarate, norethisterone acetate (LO LOESTRIN FE), both taken for unspecified indications from unknown dates. The patient previously took tobramycin (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Jul2021 at 10:30, the patient developed a full body rash with hives. Therapeutic measures were taken as a result of the event and included treatment with palliative care at home. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event full body rash with hives was not resolved at the time of this report.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, SARS-CoV-2 test
Clinical narrative: developed shingles 3 days after first vaccine shot; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 04May2021 at 09:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant past medical history. The patient had no known allergies to medications, food or other products. The patient did not receive any medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07May2021 at 09:00, the patient developed shingles 3 days after first vaccine shot. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in Jun2021, the patient underwent lab test and procedure which included antigen test (test type: nasal swab) and the result was negative. The clinical outcome of the event shingles was resolved on an unknown date in 2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.